Table 3.
Outcomes.
| All | AITL 1 | cHL 2 | |
|---|---|---|---|
| Median Follow-up, months | 23 | 12 | 24 |
| Time since ASCT, d, median (range) | 687 (24–1105) | 350 (24–1093) | 725 (594–1105) |
| OS 3 at 1 y, n (%) | 10 (83%) | 3 (60%) | 7 (100%) |
| PFS 4 at 1 y, n (%) | 8 (67%) | 3 (60%) | 5 (71%) |
| Remission status at d +100, n (%) | |||
| CR 5 | 10 (83%) | 3 (60%) | 7 (100%) |
| PR 6 | 0 (0%) | 0 (0%) | 0 (0%) |
| SD 7 | 0 (0%) | 0 (0%) | 0 (0%) |
| PD 8 | 2 (18%) | 2 (40%) | 0 (0%) |
| Death, n (%) | |||
| Due to TRM 9 | 0 (0%) | 0 (0%) | 0 (0%) |
| Due to progression | 2 (18%) | 2 (40%) | 0 (0%) |
| Due to other causes | 0 (0%) | 0 (0%) | 0 (0%) |
1 Angioimmunoblastic T-cell lymphoma; 2 classical Hodgkin lymphoma; 3 overall survival; 4 progression free survival; 5 complete response; 6 partial response; 7 stable disease; 8 progressive disease; 9 treatment-related mortality.